Categories: CareCauseDrugProduct
We develop novel mucolytic drugs to transform the treatment landscape of COPD and other lung diseases.
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| 18.02.2025 | How a Swedish startup is transforming respiratory disease treatment | COPD affects 16 million in the US and 400 million globally and is the third leading cause of death.
A core problem in COPD, Cystic fibrosis (CF), asthma, and bronchiectasis, is the overproduction of thick, sticky mucus that obstructs and pl... |
Reviews 0
